Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03812653

Sleep for Stroke Management and Recovery Trial

The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Alabama Hospital, Birmingham, Alabama, United States

Loading trial locations.

About this study

Sleep SMART has a prospective, randomized, open-label, blinded-endpoint (PROBE) design. It is a multi-site, parallel-group superiority trial that compares 6 months of OSA treatment to usual care. The study includes two trials: a prevention study with an embedded recovery trial. 3062 subjects will be randomized over 5 years at 110 sites within the NINDS-funded StrokeNet clinical trials network.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Current Inclusion Criteria, as of 6/28/2024:

  • Ischemic stroke within the prior 7 days.
  • NIH Stroke Scale Score ≥1 at the time of enrollment

Previous Inclusion Criteria, prior to 6/28/2024:

  • Ischemic stroke or TIA with ABCD ≥4, within prior 14 days.

Exclusion criteria

(for entire time period):

  • pre-event inability to perform all of own basic ADLs
  • unable to obtain informed consent from subject or legally authorized representative
  • incarcerated
  • known pregnancy
  • current mechanical ventilation (can enroll later if this resolves) or tracheostomy
  • current use of positive airway pressure, or use within one month prior to stroke
  • anatomical or dermatologic anomaly that makes use of CPAP interface unfeasible
  • severe bullous lung disease
  • history of prior spontaneous pneumothorax or current pneumothorax
  • hypotension requiring current treatment with pressors (can enroll later if this resolves)
  • other specific medical circumstances that conceivably, in the opinion of the site PI, could render the patient at risk of harm from use of CPAP
  • massive epistaxis or previous history of massive epistaxis
  • cranial surgery or head trauma within the past 6 months, with known or possible CSF leak or pneumocephalus
  • recent hemicraniectomy or suboccipital craniectomy (i.e. those whose bone has not yet been replaced), or any other recent bone removal procedure for relief of intracranial pressure
  • current receipt of oxygen supplementation >4 liters per minute
  • current contact, droplet, respiratory/airborne precautions

Treatment and study plan

CPAP

Device

Automatically-adjusting continuous positive airway pressure (CPAP) delivered using a study supplied device.

Primary outcomes

  1. Time to Event Combined Outcome: new ischemic stroke, acute coronary syndrome, or all-cause mortality

    Time frame: 6 months post randomization

    The primary outcome is a time-to-event outcome defined as a participant having at least one of the following events within 6-months from randomization: new ischemic stroke, acute coronary syndrome or all-cause mortality

  2. Modified Rankin Scale Score

    Time frame: 3 months post randomization

    Functional outcome as measured by the 9 question modified Rankin Scale (mRS-9Q). The mRS-9Q has 9 questions related to level of function. Outcomes range from 0 (no symptoms) to 6 (death).

Secondary outcomes

  1. NIH Stroke Score (NIHSS)

    Time frame: 3 months post randomization

    Neurological outcome is measured by the NIHSS. The NIHSS scale ranges from 0 (no deficits) to 42.

  2. Short Montreal Cognitive Assessment (MoCA) Score

    Time frame: 3 months post randomization

    Cognitive outcome is measured by the Short MoCA. The short MoCA is a 5 minute short version of the Montreal Cognitive Assessment (MoCA). This instrument tests phonemic verbal fluency (1 point), delayed recall (5 points), and orientation (6 points) with a score ranging from 0-12.

  3. Quality of Life outcome

    Time frame: 3 months post randomization

    Quality of life outcome is measured by the shortened Stroke Specific Quality of Life Scale (SS-QOL). The short SS-QOL has 7 domains that include physical function, language, vision, thinking, energy, mood, and role function. There is 1 question from each domain. The 12 item SS-QOL is calculated by averaging the scores of these 12 questions.

Sponsors and collaborators

Lead sponsor

University of Michigan

Other

Collaborators

  • FusionHealth LLC
  • Medical University of South Carolina
  • National Institute of Neurological Disorders and Stroke (NINDS)
  • University of Cincinnati

Registry information

Acronym: Sleep SMART

Important dates

Study start
2019
Primary completion
2026
Study completion
2026
First posted
Jan 23, 2019
Registry last updated
Feb 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.